Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Annis Allen

2. Date of Event Requiring Statement (MM/DD/YYYY) 11/3/2018

3. Issuer Name and Ticker or Trading Symbol

AILERON THERAPEUTICS INC [ALRN]

(Last) (First) (Middle)

C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
See Remarks /

(Street)

WATERTOWN, MA 02472

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7547	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	6/25/2019	Common Stock	12076	$1.30	D
Stock Option (right to buy)	⁽¹⁾	3/13/2024	Common Stock	55751	$5.07	D
Stock Option (right to buy)	⁽²⁾	3/10/2025	Common Stock	8050	$5.07	D
Stock Option (right to buy)	⁽³⁾	3/2/2027	Common Stock	24152	$5.77	D
Stock Option (right to buy)	⁽⁴⁾	7/24/2027	Common Stock	25015	$13.00	D

Explanation of Responses:
(1)	These options are fully vested.
(2)	This option was granted on March 10, 2015. The shares underlying the option vested as to 25% of the shares on January 1, 2016 and thereafter are scheduled to vest in equal monthly installments through January 1, 2020.
(3)	This option was granted on March 2, 2017. The shares underlying the option are scheduled to vest in equal monthly installments through March 2, 2021.
(4)	This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments through July 25, 2021.

Remarks:
Exhibit Index: 24.1 Power of Attorney

Senior Vice President, Research

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Annis Allen C/O AILERON THERAPEUTICS, INC. 490 ARSENAL WAY WATERTOWN, MA 02472			See Remarks

Signatures
/s/ Donald Dougherty, attorney-in-fact, for Allen Annis		11/6/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.